

Email: foi.tsdfd@nhs.net
Our Ref: TSD10771

Dear Sir/Madam

Request for Information

We are writing to confirm that we have now completed our search for the information you requested.

A copy of the information is below:

Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data?

Drug Name	<u>Total number of patients treated regardless of diagnosis</u>
Adalimumab	700
Abrocitinib	<5
Apremilast	5
Baricitinib	34
Bimekizumab	6
Brodalumab	0
Certolizumab Pegol	17
Deucravacitinib	<5
Dupilumab	82
Etanercept	98
Guselkumab	9
Infliximab	206
Ixekizumab	5
Lebrikizumab	<5
Nemolizumab	0
Risankizumab	35
Secukinumab	144
Tildrakizumab	<5
Tralokinumab	<5
Ustekinumab	266

Q2. How many patients were treated by the Dermatology or Rheumatology Departments or Clinics with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the <u>Dermatology Department</u>	Number of patients treated by the <u>Rheumatology Department</u>
Adalimumab		
Apremilast		
Baricitinib		
Bimekizumab		
Brodalumab		
Certolizumab Pegol		
Etanercept		
Guselkumab		
Infliximab		
Ixekizumab		
Risankizumab		
Secukinumab		
Ustekinumab		

The Trust is unable to provide the requested breakdown for Q2, as our Electronic Patient Record system does not allow us to extract reports showing the number of patients treated by department or clinic for the specified medicines and time period.

Q3. How many patients with Plaque Psoriasis or Psoriatic Arthritis across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with <u>Plaque Psoriasis</u>	Number patients with <u>Psoriatic Arthritis</u>
Adalimumab		
Bimekizumab		
Secukinumab		
Apremilast		
Certolizumab Pegol		
Etanercept		
Guselkumab		
Infliximab		
Ixekizumab		
Risankizumab		
Ustekinumab		
Brodalumab		
Deucravacitinib		

The Trust is unable to provide the requested breakdown for Q3, as our Electronic Patient Record system does not allow us to extract reports showing the number of patients treated by diagnosis for the specified medicines and time period.

Q4. How many patients with Atopic Dermatitis across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data?

Drug Name	<u>Atopic Dermatitis</u>
Baricitinib	
Dupilumab	
Nemolizumab	

The Trust is unable to provide the requested breakdown for Q4, as the information is not held in an extractable/reportable format. Our Electronic Patient Record system does not allow us to produce a report showing the number of patients treated with the specified medicine for Atopic Dermatitis for the requested time period.

Q5. How many patients with Hidradenitis Suppurativa across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data?

Drug Name	<u>Hidradenitis Suppurativa</u>
Adalimumab	
Bimekizumab	
Secukinumab	

The Trust is unable to provide the requested breakdown for Q5, as our Electronic Patient Record system does not allow us to extract reports showing the number of patients treated by diagnosis for the specified medicines and time period.

Low Numbers:

Where there are less than 5, we are unable to provide the exact information you require as this may enable the identification of our employees, members of the public or patients. This would constitute personal information and would be considered exempt under Section 40 of the Freedom of Information Act. Section 40 (FOI Act) provides an exemption to disclosure, where disclosure would contravene any of the Data Protection principles. This exemption is an absolute exemption that is not subject to the public interest test. Where the information relates to an individual who can be identified from that data, or from that data when added to other information, in the possession of, or likely to come into the possession of the data controller, this meets the definition of personal data as defined by the Data Protection Act.

The information supplied to you continues to be protected by the Copyright, Designs and Patents Act 1988. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting.

If you wish to discuss any of the above, please contact us, quoting the FOI reference number above.

If you are unhappy with the way in which we have handled your request, please contact the Data Protection and Freedom of Information Lead in the first instance. If you wish to make a formal complaint, you should write to our Complaints Manager at Torbay and South Devon NHS Foundation Trust, First Floor Bowyer Building, Torbay Hospital, Torquay TQ2 7AA or by email to tsdft.feedback@nhs.net

If you are not content with the outcome of your complaint or the internal review, you may apply directly to the Information Commissioner for a decision. Generally, the Information Commissioner will only make a decision once you have exhausted the complaints and/or internal review process provided by us. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF or through this link <https://ico.org.uk/global/contact-us/>

Yours sincerely,

Freedom of Information Team